BACKGROUND: Operative mortality rates are of great interest to surgeons, patients, policy makers, and payers as a metric for quality assessment. Thirty-day mortality and discharge mortality have been presumed to capture procedure-related deaths. However, many patients die after the 30-day mark or are transferred to other facilities or to home and die there, leading to the underreporting of surgically related deaths. We hypothesized that a longer period of observation would address these concerns and provide a more accurate measure of operative mortality. METHODS: We retrospectively reviewed institutional databases of patients undergoing resection for lung cancer, esophageal cancer, and mesothelioma. Mortality rates at 30 and 90 days were calculated with 95% confidence intervals (CIs). RESULTS: From 1999 to 2012, 7,646 surgical resections were performed: 6,119 for lung cancer, 1,258 for esophageal cancer, and 269 for mesothelioma. Among the different cancers and across operations, the additional mortality from day 31 to 90 (1.4%; 95% CI, 1.2% to 1.8%; n=111) was similar to that by day 30 (1.2%; 95% CI, 1.0% to 1.5%; n=95), resulting in overall 90-day mortality (2.7%; 95% CI, 2.3% to 3.1%; n=206) that was more than double the 30-day mortality. CONCLUSIONS: Among patients who have undergone operations for thoracic malignancies, mortality attributable to the operation occurs beyond the first 30 postsurgical days as well as after hospital discharge. Because cancer operations constitute a large portion of general thoracic surgery, we recommend national databases consider the inclusion of 90-day mortality in their data collection.
BACKGROUND: Operative mortality rates are of great interest to surgeons, patients, policy makers, and payers as a metric for quality assessment. Thirty-day mortality and discharge mortality have been presumed to capture procedure-related deaths. However, many patients die after the 30-day mark or are transferred to other facilities or to home and die there, leading to the underreporting of surgically related deaths. We hypothesized that a longer period of observation would address these concerns and provide a more accurate measure of operative mortality. METHODS: We retrospectively reviewed institutional databases of patients undergoing resection for lung cancer, esophageal cancer, and mesothelioma. Mortality rates at 30 and 90 days were calculated with 95% confidence intervals (CIs). RESULTS: From 1999 to 2012, 7,646 surgical resections were performed: 6,119 for lung cancer, 1,258 for esophageal cancer, and 269 for mesothelioma. Among the different cancers and across operations, the additional mortality from day 31 to 90 (1.4%; 95% CI, 1.2% to 1.8%; n=111) was similar to that by day 30 (1.2%; 95% CI, 1.0% to 1.5%; n=95), resulting in overall 90-day mortality (2.7%; 95% CI, 2.3% to 3.1%; n=206) that was more than double the 30-day mortality. CONCLUSIONS: Among patients who have undergone operations for thoracic malignancies, mortality attributable to the operation occurs beyond the first 30 postsurgical days as well as after hospital discharge. Because cancer operations constitute a large portion of general thoracic surgery, we recommend national databases consider the inclusion of 90-day mortality in their data collection.
Authors: S F Khuri; J Daley; W Henderson; K Hur; J Demakis; J B Aust; V Chong; P J Fabri; J O Gibbs; F Grover; K Hammermeister; G Irvin; G McDonald; E Passaro; L Phillips; F Scamman; J Spencer; J F Stremple Journal: Ann Surg Date: 1998-10 Impact factor: 12.969
Authors: Michael L Johnson; Howard S Gordon; Nancy J Petersen; Nelda P Wray; A Laurie Shroyer; Frederick L Grover; Jane M Geraci Journal: Med Care Date: 2002-01 Impact factor: 2.983
Authors: R A M Damhuis; B P L Wijnhoven; P W Plaisier; W J Kirkels; R Kranse; J J van Lanschot Journal: Br J Surg Date: 2012-06-20 Impact factor: 6.939
Authors: N E Verstegen; J W A Oosterhuis; D A Palma; G Rodrigues; F J Lagerwaard; A van der Elst; R Mollema; W F van Tets; A Warner; J J A Joosten; M I Amir; C J A Haasbeek; E F Smit; B J Slotman; S Senan Journal: Ann Oncol Date: 2013-02-20 Impact factor: 32.976
Authors: Helen A Powell; Laila J Tata; David R Baldwin; Rosamund A Stanley; Aamir Khakwani; Richard B Hubbard Journal: Thorax Date: 2013-05-17 Impact factor: 9.139
Authors: Silvio Däster; Savas D Soysal; Luca Koechlin; Lea Stoll; Ralph Peterli; Markus von Flüe; Christoph Ackermann Journal: Langenbecks Arch Surg Date: 2016-07-19 Impact factor: 3.445
Authors: Michele Carbone; Prasad S Adusumilli; H Richard Alexander; Paul Baas; Fabrizio Bardelli; Angela Bononi; Raphael Bueno; Emanuela Felley-Bosco; Francoise Galateau-Salle; David Jablons; Aaron S Mansfield; Michael Minaai; Marc de Perrot; Patricia Pesavento; Valerie Rusch; David T Severson; Emanuela Taioli; Anne Tsao; Gavitt Woodard; Haining Yang; Marjorie G Zauderer; Harvey I Pass Journal: CA Cancer J Clin Date: 2019-07-08 Impact factor: 508.702
Authors: John N Melvan; Manu S Sancheti; Theresa Gillespie; Dana C Nickleach; Yuan Liu; Kristin Higgins; Suresh Ramalingam; Joseph Lipscomb; Felix G Fernandez Journal: J Am Coll Surg Date: 2015-04-16 Impact factor: 6.113
Authors: Won Gi Jeong; Yun-Hyeon Kim; Jong Eun Lee; In-Jae Oh; Sang Yun Song; Kum Ju Chae; Hye Mi Park Journal: Cancer Res Treat Date: 2021-09-28 Impact factor: 5.036
Authors: Solomon A Graf; Steven B Zeliadt; Peter J Rise; Leah M Backhus; Xiao-Hua Zhou; Emily C Williams Journal: J Thorac Dis Date: 2018-03 Impact factor: 2.895
Authors: Seyer Safi; Axel Benner; Janos Walloschek; Maria Renner; Jan op den Winkel; Thomas Muley; Konstantina Storz; Hendrik Dienemann; Hans Hoffmann; Thomas Schneider Journal: PLoS One Date: 2015-04-09 Impact factor: 3.240